���ſ������2023������¼

Endpoints News—OnKure Therapeutics has lined up $60 million in a new private funding round, adding to the ���ſ������2023������¼ spinout’s bank account as it works through a Phase II trial. The startup is attempting to create an inhibitor of histone deacetylases, or HDACs, which are DNA-manipulating enzymes that alter how genes get expressed.

Wanted: entrepreneurs ready to launch startups based on innovations created in ���ſ������2023������¼’s research labs. The Embark Deep Tech Startup Creator is a new program created by Venture Partners at ���ſ������2023������¼, the commercialization arm of CU, to match business minds outside the university with breakthrough inventions created within its walls.

As a first-generation college student turned molecular biologist, Brian DeDecker imagines a day when humble soybeans beans, which his family has grown for generations, pack a bounty of therapeutic but hard-to-obtain natural compounds.

FDA—Flow imaging software from Theodore W. Randolph's (College of Engineering and Applied Sciences) lab and licensed to SentrySciences to create their ParticleSentryAI product was recently highlighted by the FDA in advancing drug product quality.

PV Magazine—Brek Electronics, a ���ſ������2023������¼ spinout, has developed two string inverters with its novel composite architecture optimized for silicon carbide (SiC) components.

Commercialization activities led by Venture Partners at the ���ſ������2023������¼ had an economic impact of $8 billion nationally and $5.2 billion in the state of Colorado over the last five years, according to a new report from the Leeds School of Business.

From Tech Transfer Central — Since launching its Licensing with EASE® express agreement for start-up entrepreneurs in 2018, ���ſ������2023������¼ has seen its number of startups “increase dramatically,” according to Brynmor Rees, associate vice chancellor for research & innovation and managing director of Venture Partners.